Welcome to our dedicated page for Neuraxis news (Ticker: NRXS), a resource for investors and traders seeking the latest updates and insights on Neuraxis stock.
Neuraxis Inc (NRXS) pioneers neuromodulation therapies targeting pediatric gut-brain disorders through its FDA-cleared IB-Stim® technology. This hub provides investors and medical professionals with essential updates on clinical advancements, regulatory developments, and strategic initiatives driving innovation in neurogastroenterology.
Access timely press releases covering pivotal milestones including clinical trial outcomes, partnership announcements, and peer-reviewed research publications. Our curated news collection enables efficient tracking of the company’s evidence-based approach to treating functional abdominal pain and related conditions in pediatric populations.
Key updates about PENFS technology applications, intellectual property developments, and healthcare collaborations are maintained here for due diligence and market analysis. Bookmark this page to monitor NRXS’s progress in advancing non-pharmacological solutions for chronic gut-brain interaction disorders.
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025. The company will release its financial results for the period ended March 31, 2025, before the market opens.
A conference call to discuss the results will be held the same day at 9:00 AM ET. Interested parties can access the call through a live webcast on the company's investor relations website or via dial-in registration. A replay will be available on the company's website following the call.
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in children and adults, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025.
CEO Brian Carico will deliver a presentation on Wednesday, April 23, 2025, at 11:00 AM EST and conduct 1x1 investor meetings on Thursday, April 24, 2025. The in-person meetings will take place at the Paris Hotel & Casino in Las Vegas. The presentation will be available via webcast, and investors interested in scheduling meetings must register through the conference platform.
NeurAxis (NYSE: NRXS) reported strong Q4 2024 financial results with revenues increasing 43% to $761,000 compared to Q4 2023. The company's operating loss improved by 10% year-over-year.
Key operational highlights include expanding covered lives to 51 million from 4 million in 2023, receiving a new CPT Category I code for PENFS procedures effective January 2026, and FDA clearance for expanded IB-Stim label (ages 8-21) and the rectal expulsion device (RED).
Financial metrics for FY2024 show:
- Annual revenue of $2.7 million, up 9% from 2023
- Gross margin of 86.5%
- Operating loss of $7.2 million
- Cash balance of $3.7 million as of December 31, 2024
The company treated over 1,000 pediatric patients in the past 12 months, representing 0.1% of the 600,000 children suffering from IBS in the U.S.
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for Thursday, March 20, 2025, before market open.
The company will host a conference call at 9:00 AM ET on the same day to discuss the results. Investors can access the call through a live webcast available on the company's investor relations website or through a dial-in option after registration. Questions can be submitted through the webcast portal or via email to NRXS@lythampartners.com.
NeurAxis (NYSE: NRXS) has secured medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology with a major insurer, extending coverage to approximately 5.1 million members across 13 states, including MI, IL, NY, and TX.
The company's IB-Stim device, which is FDA-cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in patients aged 8-21 years, delivers gentle electrical impulses to cranial nerve bundles in the ear. This non-surgical treatment is particularly significant as there are currently no FDA-approved drug therapies for children with abdominal pain-related gut-brain interaction disorders.
NeurAxis has expanded its insurance coverage from 4 million to 51 million lives over the past year, positioning the company to serve approximately 600,000 individuals suffering from IBS.
NeurAxis (NYSE: NRXS) has announced medical policy coverage with Molina Healthcare for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim. The coverage extends to Molina's approximately 5.1 million members across 13 states, including Michigan, Illinois, New York, and Texas.
IB-Stim is an FDA-cleared, non-surgical device that treats functional abdominal pain associated with irritable bowel syndrome (IBS) in patients aged 8-21 years through gentle electrical impulses to cranial nerve bundles in the ear. This treatment is particularly significant as there are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction.
The company has notably expanded its insurance coverage from 4 million to 51 million lives over the past year, with potential to treat approximately 600,000 individuals suffering from IBS.
NeurAxis has issued a letter to shareholders, highlighting significant achievements in 2024 and plans for 2025. The company focuses on commercializing IB-Stim for pediatric IBS and advancing the RED device for chronic constipation. In 2024, IB-Stim, supported by PENFS technology, treated about 1,000 patients and expanded insurance coverage from 4 million to 51 million lives, significantly boosting revenues. The FDA recently expanded IB-Stim's indication to ages 8-21, increasing its market by 75%. A new CPT Category I code for PENFS will take effect in 2026, enhancing patient access. Additionally, the FDA cleared the RED device for US commercialization, with initial revenues expected in Q1 2025. NeurAxis aims to achieve cash flow breakeven by 2026, supported by strong sales growth, disciplined cost management, and recent investments from healthcare funds.
NeurAxis (NYSE: NRXS) reported preliminary Q4 2024 results showing significant growth. Q4 revenues reached approximately $800,000, marking a 50% increase compared to Q4 2023, accelerating from 40% growth in Q3. Full-year 2024 revenues were approximately $2.7 million, up 11% year-over-year.
The company's IB-Stim technology, supported by 16 peer-reviewed studies from leading U.S. children's hospitals, has expanded insurance coverage to approximately 45 million lives, up from 4 million a year ago. The company ended 2024 with a cash balance of $3.7 million.
Recent developments include FDA 510(k) clearance expanding IB-Stim's indication to patients aged 8-21 years (previously 11-18 years), new Category I CPT code for PENFS procedures, and upcoming commercialization of the FDA-approved Rectal Expulsion Device in Q1 2025.
NeurAxis Inc (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in children and adults, has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit.
CEO Brian Carrico will deliver a company presentation on Monday, January 13, 2025, at 2:30 PM Eastern time. The virtual event will be accessible via webcast through the conference homepage or directly through a dedicated link. A replay option will be available following the presentation.
Interested investors can request one-on-one meetings after the event by contacting the provided email address.
FAQ
What is the current stock price of Neuraxis (NRXS)?
What is the market cap of Neuraxis (NRXS)?
